Novacyt (LON:NCYT – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported GBX (8) EPS for the quarter, Digital Look Earnings reports. Novacyt had a negative net margin of 103.08% and a negative return on equity of 96.44%.
Novacyt Trading Down 7.5%
Novacyt stock traded down GBX 3 during midday trading on Friday, reaching GBX 37. The stock had a trading volume of 121,683 shares, compared to its average volume of 174,251. Novacyt has a twelve month low of GBX 26.60 and a twelve month high of GBX 86. The company has a debt-to-equity ratio of 44.74, a current ratio of 4.74 and a quick ratio of 4.46. The firm has a market cap of £26.83 million, a price-to-earnings ratio of -1.16 and a beta of 1.11. The firm’s fifty day simple moving average is GBX 41.85 and its two-hundred day simple moving average is GBX 39.18.
About Novacyt
The Company is divided into three business segments:
Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments
Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.
See Also
- Five stocks we like better than Novacyt
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Novacyt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novacyt and related companies with MarketBeat.com's FREE daily email newsletter.
